Relay Therapeutics to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this month at the Cowen 3rd Annual Oncology Innovation Summit on Thursday, June 2, 2022, at 11:30 a.m. ET and at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022, at 5:40 p.m. ET.

Both the Cowen 3rd Annual Oncology Innovation Summit and the Goldman Sachs 43rd Annual Global Healthcare Conference will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following each event.

About Relay TherapeuticsRelay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicines company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of disparate technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.

Contact:Caroline Glen617-370-8837[email protected]

Media:Dan Budwick1AB973-271-6085[email protected]

You May Also Be Interested In

• Crypto News Today: AlphaPepe Presale Nears Sellout With 11,000 Buyers While XRP Price Prediction Eyes $10
• Davis Commodities Limited Announces Receipt of Nasdaq Final Action Letter
• Relay Therapeutics (RLAY) PT Raised to $31 at JPMorgan